Voyager Therapeutics, Inc.
Treatment of amyotrophic lateral sclerosis (ALS)

Last updated:

Abstract:

The present invention relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and/or canine degenerative myelopathy (DM).

Status:
Grant
Type:

Utility

Filling date:

16 Oct 2018

Issue date:

6 Sep 2022